Pharmaceutical giant Eli Lilly has recently announced that it will be revealing date from more than fifty studies at the up and coming 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida from May 29 to June 2 2009

The majority of the presentations will relate to the cancer research studies that Lilly is known for, and the company will also unveil further details about its breakthrough drug Alimta, which has been used to treat cancers including mesothelioma.

Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader, said: “ASCO’s theme of ‘Personalizing Cancer Care’ is one to which Lilly has subscribed for many years. We are focused on delivering what we call ‘tailored therapies’ – an essential component of personalized medicine – to identify patients who are most likely to respond to therapy, and just as importantly, which patients will not.”

He added: “With ASCO studies focusing on non-small cell lung cancer, breast cancer, cervical cancer and biliary tract cancer, among others, Lilly will demonstrate its continued commitment to meeting the needs of patients across a broad oncology spectrum.”

Be Sociable, Share!